14
Participants
Start Date
August 31, 2011
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Lu-177-DOTA-girentuximab
"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
Radboud University Medical Center, Nijmegen
Radboud University Medical Center
OTHER